Physician profile
Fnu Sandhia
NPI 1154842813
$826.23
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $44.11 · 2021: $125 · 2022: $267 · 2023: $262 · 2024: $128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $390.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $153.55 | 2022-2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $77.30 | 2020-2024 | |
| Sanofi Pasteur INC. | $75.53 | 2020-2024 | |
| Neurelis, INC. | $71.15 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $70.42 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $60.44 | 2022-2023 | |
| Supernus Pharmaceuticals, INC. | $56.86 | 2023-2024 | Qelbree, Qelbree |
| Adlon Therapeutics L.P. | $53.43 | 2021 | |
| Seqirus USA INC | $48.87 | 2021-2022 | |
| Cranial Technologies, INC | $42.90 | 2023 | Doc Band |
| Glaxosmithkline, LLC. | $28.02 | 2021-2023 | Bexsero |
| Merck Sharp & Dohme LLC | $27.84 | 2021-2022 | |
| Biomarin Pharmaceutical INC. | $20.16 | 2024 | Voxzogo 1.2mg |
| Radiometer America, INC | $16.48 | 2020 | |
| Sanofi-Aventis U.S. LLC | $13.21 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $10.07 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fnu Sandhia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.